Apellis Pharmaceuticals (APLS) Receiving Somewhat Positive Media Coverage, Study Shows

Headlines about Apellis Pharmaceuticals (NASDAQ:APLS) have trended somewhat positive on Saturday, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Apellis Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.1589561319934 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Shares of Apellis Pharmaceuticals (NASDAQ:APLS) traded down $1.00 during midday trading on Friday, hitting $14.01. The stock had a trading volume of 107,265 shares, compared to its average volume of 74,553. Apellis Pharmaceuticals has a 1-year low of $12.45 and a 1-year high of $25.49.

Several brokerages have recently weighed in on APLS. B. Riley began coverage on Apellis Pharmaceuticals in a research report on Thursday. They set a “buy” rating and a $27.00 target price on the stock. Evercore ISI began coverage on Apellis Pharmaceuticals in a research report on Monday, December 4th. They set an “outperform” rating on the stock. Citigroup began coverage on Apellis Pharmaceuticals in a research report on Monday, December 4th. They set a “buy” rating and a $23.00 target price on the stock. Finally, JPMorgan Chase & Co. began coverage on Apellis Pharmaceuticals in a research report on Monday, December 4th. They set an “overweight” rating and a $31.00 target price on the stock.

In other Apellis Pharmaceuticals news, major shareholder Global Strategic Fund I. Venbio bought 127,515 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were acquired at an average price of $14.00 per share, with a total value of $1,785,210.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

COPYRIGHT VIOLATION NOTICE: “Apellis Pharmaceuticals (APLS) Receiving Somewhat Positive Media Coverage, Study Shows” was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.com-unik.info/2018/02/10/apellis-pharmaceuticals-apls-receiving-somewhat-positive-media-coverage-study-shows.html.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company’s lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade.

Insider Buying and Selling by Quarter for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit